Target intelligence / Profile preview

Novel protein, readthrough between VTN and SEBOX (ENSG00000273171; also UniProtKB: H0YJW9)

Target
ENSG00000273171; also UniProtKB: H0YJW9
Molecular classification
Other (readthrough transcript/protein of unknown function)
01

Overview

This gene represents a computationally annotated readthrough transcript merging the VTN (vitronectin) and SEBOX (SEBOX homeobox) loci on chromosome 17. Such readthrough or "chimeric" transcripts can arise during transcription when the RNA polymerase ignores canonical termination signals and continues into adjacent gene loci, producing a hybrid mRNA molecule. The corresponding predicted protein is unvalidated, has no characterized function, no membership in any established protein family, and is not recognized as a molecular target for pharmacological agents. Current data categorizations (GeneCards, Ensembl, Protein Atlas) emphasize the absence of functional, tissue-specific, or disease-relevant information, and there is no evidence for its existence as a stable, functional protein product. Its annotation likely reflects automated genome annotation pipelines, and use as a molecular target or biomarker is not supported by the scientific literature. If you need a validated target related to VTN or SEBOX, queries should focus on vitronectin or SEBOX homeobox individually, which are established proteins with biological functions and target associations.

Other names
AC002094.3H0YJW9GC17M027144GC17M028366

Beyond the preview

Go deeper on Novel protein, readthrough between VTN and SEBOX (ENSG00000273171; also UniProtKB: H0YJW9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel protein, readthrough between VTN and SEBOX (ENSG00000273171; also UniProtKB: H0YJW9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call